Peripheral Arterial Occlusive Disease (PAOD)
Clinical Trial Phase I/IIa
Peripheral arterial occlusive disease (PAOD) is a chronic vascular disease of the arteries, mainly caused by arteriosclerosis and predominantly affecting the arteries of the lower limb. During the course of the disease, the arteries supplying the extremities become narrow (stenosis) or clogged (occlusion). The arterial stenosis or occlusion leads to blood flow reduction and hence to limited oxygen supply in the area supplied by the affected arteries. The resulting ischemia leads to numbness, pain and hazardous infections in developing ulcers (Peripheral Arterial Disease, Merck Manual of Diagnosis and Therapy, Professional Edition, 2018).
Based on their anti-inflammatory and pro-angiogenic properties, ABCB5-positive (ABCB5+) mesenchymal stem cells (MSCs) exhibit a strong regeneration potential. In several experimental models, ABCB5+ MSCs have been shown to play a significant role in angiogenesis and neo-vascularization (VanderBeken et al., submitted). Thus, administration of ABCB5+ MSCs could restore blood supply and improve would healing in patients with PAOD.
In scientific collaboration with the University Clinic of Ulm (Prof. Dr. Karin Scharffetter-Kochanek), the Boston Children’s Hospital (Markus Frank, MD), the Havard Stem Cell Institute (George F. Murphy, MD) and the Brigham and Womens‘ Hospital, Boston (Dennis Orgill, MD, PhD), RHEACELL could show in several preclinical studies that the high-purity ABCB5+ MSCs can contribute to improved wound healing. In models of acute and chronic cutaneous wounds, application of ABCB5+ MSCs accelerated wound healing and improved scar tissue quality (Vander Beken et al., submitted).
HERE you can find more information about the clinical trial with allogeneic ABCB5+ MSCs.